Universal Brain Inc.

Universal Brain Inc. develops a medical-grade EEG system designed for precision psychiatry, focusing on objective, brain-based diagnosis and treatment of psychiatric conditions, primarily depression. The company has engineered a next-generation EEG wearable headset that captures event-related potentials (ERPs)—brain responses to cognitive and emotional stimuli—and pairs it with Neurotique™, a proprietary digital interface and AI-driven software algorithm that translates raw EEG data into actionable clinical insights. The platform enables neurotyping: the classification of patients based on functional brain measures derived from EEG, allowing clinicians to identify subtypes of psychiatric disorders and tailor treatment accordingly. Universal Brain's approach addresses the heterogeneity of psychiatric conditions by examining core neural systems including attention, memory, and emotional processing. The system is currently investigational and intended for use in clinical settings to aid treatment decision-making and support psychiatric clinical drug trials. The company's leadership includes a psychiatrist founder/CEO (Kazu Okuda, M.D.) and Chief Scientist with expertise in clinical neuroscience (Greg Hajcak, Ph.D.), indicating strong research-clinical integration. The platform represents a shift toward objective, neurobiological markers rather than symptom-based diagnosis alone.